Loading...
Loading...
The joint venture between Biogen
BIIB and Samsung BioLogics, Samsung Bioepis, has been granted
European Commission (EC) approval for BENEPALI® , an
etanercept biosimilar referencing Enbrel®i. BENEPALI has been
granted marketing authorization in the European Union (EU) for the
treatment of adults with moderate to severe rheumatoid arthritis (RA),
psoriatic arthritis, non-radiographic axial spondyloarthritis and plaque
psoriasis. Biogen intends to make BENEPALI available for patients in the
coming weeks.
BENEPALI is the first etanercept biosimilar referencing Enbrel to be
approved in the EU, making it the first subcutaneous anti-TNF biosimilar
available there. Anti-TNF's are the largest component of the EU
biologics market, accounting for approximately $10 billion of
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in